Evolution of acquired resistance in a ROS1+ KRAS G12C+ NSCLC through the MAPK pathway

Evolution of acquired resistance in a ROS1+ KRAS G12C+ NSCLC through the MAPK pathway

Abstract Patients with metastatic NSCLC bearing a ROS1 gene fusion usually experience prolonged disease control with ROS1-targeting tyrosine kinase inhibitors (TKI), but significant clinical heterogeneity exists in part due to the presence of co-occurring genomic alterations. Here, we report on a pa...

Full description

Bibliographic Details
Main Authors: Katherine Priest, Anh Le, Amanuail Gebregzabheir, Hala Nijmeh, Gregory B. Reis, Melanie Mandell, Kurtis D. Davies, Carolyn Lawrence, Emily O’Donnell, Robert C. Doebele, Liming Bao, Dara L. Aisner, Erin L. Schenk
Format: Article
Language:English
Published: Nature Portfolio 2023-01-01
Series:npj Precision Oncology
Online Access:https://doi.org/10.1038/s41698-023-00349-0

Internet

https://doi.org/10.1038/s41698-023-00349-0

Similar Items